Business Wire

When Regulation and AI Converge: SymphonyAI Joins the FCA Supercharged Sandbox to Pioneer Responsible Fintech Innovation

19.11.2025 08:00:00 CET | Business Wire | Press Release

Share

SymphonyAI, a global leader in Vertical AI product platforms, has been selected to participate in the UK’s Financial Conduct Authority’s (FCA) Supercharged AI Sandbox, a new initiative enabling firms to safely develop and test advanced AI technologies using NVIDIA (NVDA) accelerated computing within a supervised regulatory environment.

SymphonyAI Financial Services was selected following a competitive application process that evaluated proposed use cases for innovation potential, technical feasibility, and regulatory impact.

Running from September 2025 to January 2026, the Sandbox offers a secure, structured environment for experimentation on next-generation AI use cases. SymphonyAI is developing an AI agent concept powered by small language models and reinforcement learning, designed to advance the intelligence and autonomy of financial services agents. If successful, the innovations developed in the Sandbox will be incorporated into SymphonyAI’s portfolio of intelligent financial services agents, further enhancing how financial institutions accelerate risk detection, improve compliance, and reduce investigation time.

“SymphonyAI has long been at the forefront of AI innovation in regulated industries,” said Jason Shane, Head of Product, Strategy and Innovation, Financial Services, SymphonyAI. “Our participation in the FCA’s sandbox programme underscores our leadership in Financial Services AI and our commitment to advancing responsible, explainable innovation. By incorporating these next-generation learnings directly into our AI agents, we’re giving customers the fastest, safest way to access the most advanced AI capabilities available, ensuring they stay ahead in risk management, compliance, and operational performance.”

Through its participation, SymphonyAI aims to:

  • Incubate a new AI innovation to benefit the financial crime risk and compliance community;
  • Accelerate the integration of next-generation AI agent capabilities, combining generative models, reinforcement learning, and domain-trained models, into our Sensa Risk Intelligence platform and broader Financial Services portfolio;
  • Collaborate with the FCA and industry peers to establish trusted and explainable AI innovation(s), that improve(s) the accuracy of outcomes and can securely scale in highly regulated financial services environments.

The 12-week program will culminate in showcase days on 28–29 January 2026 in London, where participants will present their innovations to regulators, financial institutions, academia, consultancies, and government representatives.

About the FCA’s Supercharged Sandbox

For more information about the FCA's Supercharged Sandbox, please visit: www.fca.org.uk/firms/innovation/ai-lab

SymphonyAI Participation Timeline

  • 30 September 2025: Virtual kickoff and bootcamp
  • 30 September 2025 – 9 January 2026: Tech sprint / development phase
  • 28–29 January 2026: Showcase days in London

About SymphonyAI

SymphonyAI delivers Vertical AI product platforms that help enterprises solve their most complex, high-value challenges — from stopping financial crime to improving store -performance and boosting manufacturing efficiency. Trusted by more than 2,000 enterprise customers worldwide, including 200 of the top financial institutions, the top 25 CPG companies, and many of the world’s largest grocers and industrial manufacturers, SymphonyAI provides domain-trained applications and pre-built agents that are ready to work on day one. Learn more at https://www.symphonyai.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251118157541/en/

Contacts

Media Contact
SymphonyAI
Media@symphonyai.com

Treble -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ftreblepr.com&e
sheet=54360393&newsitemid=20251118157541&lan=en-US&anchor=Treble&index=6&md5=484
0ff1c4327552412c647b3a0c14475
Sarah Vandiver
symphonyai@treblepr.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press Release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press Release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press Release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye